Kourtney Kardashian’s health and wellness supplement company Lemme made a fair amount of noise earlier in the week when it announced its promising weight loss product and the first drop we’ve seen flat-out called a GLP-1 supplement with Lemme GLP-1 Daily. The primary driver in the innovation and ingredient responsible for the GLP-1 claims and marketing is the patented Eriomin lemon extract, which is not something we’ve seen in a formula before, although, to be fair, it didn’t recently come to market.
With Lemme GLP-1 Daily getting so much attention, we figured we’d dive a bit into Eriomin as it packs a serious punch when it comes to managing blood sugar levels and supporting overall metabolic health. This lemon flavonoid blend has been shown to boost GLP-1 levels naturally, which is a big deal for anyone looking to keep their glucose in check. In clinical trials, participants saw an impressive 17 to 22% increase in GLP-1 after just 12 weeks of supplementation. Eriomin doesn’t stop there; it also helps improve insulin sensitivity, reduce inflammation, and even supports antioxidant activity in the body.
Taking things even further, Eriomin, found in Lemme’s latest supplement GLP-1 Daily, has a triple-pronged approach to prediabetes. Along with supporting blood sugar, it addresses oxidative stress and inflammation, which are key players in metabolic health. One study showed that 24% of participants actually and incredibly reversed their prediabetic condition after using Eriomin; plus, it’s been found to positively impact gut health by increasing beneficial bacteria associated with better glycemic control.
For anyone concerned about blood sugar, looking to support their metabolic health, and improve weight management without stimulants, Eriomin offers a science-backed, natural solution that’s easy to incorporate into daily life via supplementation. Again, we haven’t seen Eriomin in any nutrition product, at least for now, with Lemme GLP-1 Daily being the first that’s come across our desk, although we imagine it won’t take long for others to get on board, especially with the popularity around GLP-1 agonists.
